Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL348441 | 0.87 | ALDH1A1 (0.56) | ALDH1A1KDM4ELMNAL3MBTL1HPGD | |
| SCHEMBL7198913 | 0.87 | ALDH1A1 (0.55) | ALDH1A1KDM4ELMNAL3MBTL1HPGD | |
| SCHEMBL7192146 | 0.86 | ALDH1A1 (0.61) | ALDH1A1KDM4ELMNAL3MBTL1HPGD | |
| SCHEMBL7190164 | 0.85 | ALDH1A1 (0.60) | ALDH1A1KDM4ELMNAL3MBTL1HPGD | |
| SCHEMBL13331128 | 0.85 | ALDH1A1 (0.59) | ALDH1A1KDM4ELMNAL3MBTL1HPGD | |
| SCHEMBL13619485 | 0.85 | ALDH1A1 (0.59) | ALDH1A1KDM4ELMNAL3MBTL1HPGD | |
| SCHEMBL8240159 | 0.85 | ALDH1A1 (0.59) | ALDH1A1KDM4ELMNAL3MBTL1HPGD | |
| SCHEMBL14186062 | 0.84 | ALDH1A1 (0.63) | ALDH1A1KDM4ELMNAL3MBTL1HPGD | |
| SCHEMBL3834631 | 0.84 | ALDH1A1 (0.54) | ALDH1A1KDM4ELMNAL3MBTL1HPGD | |
| SCHEMBL7190225 | 0.82 | ROCK2 (0.48) | ALDH1A1KDM4ELMNAMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6589972-B2 | Anticancer agents, osteoporosis, arteriosclerosis, restnosis,vision defects | BAYER AKTIENGESELLSCHAFT (DE) | 2003-07-08 | — | — | US | disclosed |
| EP-1147079-A2 | BETA-PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2001-10-24 | — | — | EP | disclosed |
| US-20010031788-A1 | Beta-phenylalanine derivatives as integrin antagonists | SCHOOP ANDREAS (DE) | 2001-10-18 | — | — | US | disclosed |
| US-6291503-B1 | β-phenylalanine derivatives as integrin antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-18 | — | — | US | disclosed |
| WO-2000041469-A2 | β-PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031788-A1 | Beta-phenylalanine derivatives as integrin antagonists | ITGB4, ITGA4, ITGB2 | ALDH1A1 2010/4885KDM4E 360/4885LMNA 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.